A Randomized Phase II Trial of Erlotinib Alone or in Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Sep 2020 Status changed from active, no longer recruiting to completed.
- 24 Jul 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 21 Feb 2019 Planned primary completion date changed from 1 Jul 2018 to 15 Feb 2020.